首页 | 本学科首页   官方微博 | 高级检索  
检索        

辛伐他汀在不稳定型心绞痛患者早期应用的疗效
引用本文:高智耀,雷兆军,李亚军,王晓明.辛伐他汀在不稳定型心绞痛患者早期应用的疗效[J].心脏杂志,2004,16(2):140-142.
作者姓名:高智耀  雷兆军  李亚军  王晓明
作者单位:1. 延安大学医学院第二附属医院心内科,陕西,绥德718000
2. 核工业咸阳215医院,陕西,咸阳,712000
3. 第四军医大学西京医院老年病科,陕西,西安,710032
摘    要:目的 :探讨辛伐他汀对不稳定型心绞痛 (UAP)发生早期 (2 4~ 96 h)开始应用的疗效及安全性。方法 :临床确诊为 UAP患者 89例 ,随机分为对照组 (常规治疗 ,4 5例 ) ,辛伐他汀组 (常规治疗外 ,加服辛伐他汀 ,4 4例 ) ,于治疗前、治疗后 3、6和 12个月时分别测肝功、肾功、肌酶谱、总胆固醇 (TC)、低密度脂蛋白胆固醇 (L DL - C)、一氧化氮(NO)、C-反应蛋白 (CRP)、高密度脂蛋白胆固醇 (HDL - C) ,2 4 h Holter检测心肌缺血总负荷 (TIB)和心血管缺血相关事件。结果 :辛伐他汀 6个月后能有效地降低 UAP患者血清 TC、L DL - C、CRP,升高 NO,HL D- C,与对照组比较有显著性差异 (P<0 .0 1) ;两组患者每周心绞痛发作次数及 TIB均有减少 ,但辛伐他汀组更明显 (P<0 .0 5 ) ;其缺血相关事件亦有显著性差异 (P<0 .0 1)。辛伐他汀组中有 4例轻度转氨酶升高 ,2例出现腹胀。结论 :U AP发病早期应用辛伐他汀能安全、有效地降低血脂和 CRP,升高 NO,显著减少心血管缺血相关事件发生率。

关 键 词:心绞痛  不稳定型    血脂    辛伐他汀
文章编号:1009-7236(2004)02-0140-03
修稿时间:2003年3月31日

Efficacy and safety of Simvastatin in early-period of unstable angina pectoris
GAO Zhi-yao,LEI Zhao-jun,LI Ya-jun,WANG Xiao-ming.Efficacy and safety of Simvastatin in early-period of unstable angina pectoris[J].Chinese Heart Journal,2004,16(2):140-142.
Authors:GAO Zhi-yao  LEI Zhao-jun  LI Ya-jun  WANG Xiao-ming
Institution:GAO Zhi-yao1,LEI Zhao-jun2,LI Ya-jun1,WANG Xiao-ming3
Abstract:AIM: To explore the effect and safety of Simvastatin on patients with unstable angina pectoris (UAP) in early-period (24~96 h). METHODS: Eighty-nine patients with UAP were randomly divided into control group (with conventional drugs, n=45) and Simvastatin group (with conventional drugs and Simvastatin, n=44). It was tested myocardial enzymy, liver function, kidney function, total cholesterol (TC), Low-density lipoprotein cholesterol (LDL-C), Nitric oxide (NO), C-reactive protein (CRP), high-density lipoprotein cholesterol (HDL-C) and underwent total ischemic burden (TIB) monitoring from 24 hour ambulatory electrcardigram recording and observation of ischemia related events before and 3?6 and 12 months after therapy. RESULTS: The serum TC, LDL-C, CRP in Simvastatin group were obviously decrease than the control group after 6, 12 months of therapy (P<0.01), yet the serum NO, HDL-C were markly increased after 12-month treatment (P<0.05). After treatment, frequency of angina pectoris and TIB of both groups were decreased, but the Simvastatin group was further (P<0.05), so as of acute myocardial infarction (P<0.05). Four patients had slight elavation of ALT and 2 had abdominal distension in Simvastation group. CONCLUSION: Simvastatin is a effect and safety drug to take anti-myocardial ischemic and lipid-lowering, also can reduce the ischemia related events.
Keywords:angina pectoris  unstable  serum lipid  Simvastatin
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《心脏杂志》浏览原始摘要信息
点击此处可从《心脏杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号